FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315619061> ?p ?o ?g. }

• W4315619061 endingPage "e0280044" @default.
• W4315619061 startingPage "e0280044" @default.
• W4315619061 abstract "Introduction Diffuse large B-cell lymphoma (DLBCL) is a high grade non-Hodgkin lymphoma which is common among immunodeficient people. Derangements of peripheral blood immune cells have been described to have a prognostic impact in DLBCL in high income countries, including a monocytosis, the ratios of lymphocytes to both monocytes (L:M) and neutrophils (N:L), as well as the numbers of regulatory T-cells (Tregs) and immunosuppressive monocytes (HLA-DR low monos). To date, the impact of these variables has not been assessed in the setting of HIV-associated DLBCL (HIV-DLBCL), which is among the most common malignancies seen in people living with HIV. In this study, we assessed these factors in a cohort of South African patients with DLBCL and a high HIV-seropositivity-rate. In addition, we evaluated the prognostic value of monocyte activation (as reflected by monocyte fluorescence (MO-Y) on a Sysmex haematology analyser). This parameter has to date not been assessed in the setting of DLBCL. Methods A full blood count and differential count as well as flow cytometry for HLA-DR low monocyte and Treg enumeration were performed in patients with incident DLBCL referred to the Chris Hani Baragwanath Academic Hospital in Johannesburg, South Africa between November 2019 and May 2022. Additional clinical and laboratory data were recorded from the patient charts and laboratory information system. Results Seventy-six patients were included, of whom 81.3% were people living with HIV with a median CD4 count of 148 cells/ul. Most patients had advanced stage disease (74.8%) and were predominantly treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy (without Rituximab). At a median follow-up period of 19 months, the median survival time was 3.5 months, with a 12-month survival rate of 27.0%. All of the immune-cell-related variables (with the exception of the CD4 count) were similar between the people living with HIV and the HIV-negative individuals. In contrast to previous studies, a high monocyte count, the L:M and increased numbers of HLA-DR low monocytes were not significantly associated with survival in HIV-DLBCL, while a neutrophilia (>8 x 10 9 /L), the N:L (>6:1), high numbers of Tregs (≥5.17% of CD4s) and lymphopenia (<1.3 x 10 9 /L) were. In addition, increased monocyte fluorescence (MO-Y >115.5) was associated with superior outcomes, which we speculate to reflect a more robust antitumour immune response among individuals with high levels of monocyte activation. On Cox Proportional hazard analysis, immune-cell factors independently associated with survival included a CD4 count <150 cells/ul and a neutrophilia. Conclusion The monocyte count, L:M and the number of HLA-DR low monos are not strong prognostic indicators in HIV-DLBCL, while a low CD4 count and neutrophilia are. Elevation of the MO-Y shows some promise as a potential biomarker of antitumour immunity; further study in this regard would be of interest." @default.
• W4315619061 created "2023-01-12" @default.
• W4315619061 creator A5017065479 @default.
• W4315619061 creator A5028322758 @default.
• W4315619061 creator A5042358547 @default.
• W4315619061 creator A5045205946 @default.
• W4315619061 creator A5076654315 @default.
• W4315619061 date "2023-01-11" @default.
• W4315619061 modified "2023-10-18" @default.
• W4315619061 title "The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma" @default.
• W4315619061 cites W1564398196 @default.
• W4315619061 cites W1756275312 @default.
• W4315619061 cites W1969906182 @default.
• W4315619061 cites W1977342027 @default.
• W4315619061 cites W1988685968 @default.
• W4315619061 cites W1994047615 @default.
• W4315619061 cites W2013575415 @default.
• W4315619061 cites W2018076768 @default.
• W4315619061 cites W2034949380 @default.
• W4315619061 cites W2037509262 @default.
• W4315619061 cites W2037796411 @default.
• W4315619061 cites W2040113238 @default.
• W4315619061 cites W2064730985 @default.
• W4315619061 cites W2075703130 @default.
• W4315619061 cites W2106059704 @default.
• W4315619061 cites W2110334963 @default.
• W4315619061 cites W2141303698 @default.
• W4315619061 cites W2158267770 @default.
• W4315619061 cites W2177179095 @default.
• W4315619061 cites W2401477561 @default.
• W4315619061 cites W2402627636 @default.
• W4315619061 cites W2522984597 @default.
• W4315619061 cites W2561016340 @default.
• W4315619061 cites W2566922644 @default.
• W4315619061 cites W2777939499 @default.
• W4315619061 cites W2888210040 @default.
• W4315619061 cites W2980981529 @default.
• W4315619061 cites W3016548443 @default.
• W4315619061 cites W3046411970 @default.
• W4315619061 cites W4205339182 @default.
• W4315619061 cites W4211067222 @default.
• W4315619061 cites W4212897900 @default.
• W4315619061 cites W4289445521 @default.
• W4315619061 doi "https://doi.org/10.1371/journal.pone.0280044" @default.
• W4315619061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36630466" @default.
• W4315619061 hasPublicationYear "2023" @default.
• W4315619061 type Work @default.
• W4315619061 citedByCount "0" @default.
• W4315619061 crossrefType "journal-article" @default.
• W4315619061 hasAuthorship W4315619061A5017065479 @default.
• W4315619061 hasAuthorship W4315619061A5028322758 @default.
• W4315619061 hasAuthorship W4315619061A5042358547 @default.
• W4315619061 hasAuthorship W4315619061A5045205946 @default.
• W4315619061 hasAuthorship W4315619061A5076654315 @default.
• W4315619061 hasBestOaLocation W43156190611 @default.
• W4315619061 hasConcept C126322002 @default.
• W4315619061 hasConcept C143998085 @default.
• W4315619061 hasConcept C194409129 @default.
• W4315619061 hasConcept C196166836 @default.
• W4315619061 hasConcept C203014093 @default.
• W4315619061 hasConcept C2778559949 @default.
• W4315619061 hasConcept C2779338263 @default.
• W4315619061 hasConcept C2780007613 @default.
• W4315619061 hasConcept C2781087989 @default.
• W4315619061 hasConcept C2781184567 @default.
• W4315619061 hasConcept C553184892 @default.
• W4315619061 hasConcept C71924100 @default.
• W4315619061 hasConcept C8891405 @default.
• W4315619061 hasConceptScore W4315619061C126322002 @default.
• W4315619061 hasConceptScore W4315619061C143998085 @default.
• W4315619061 hasConceptScore W4315619061C194409129 @default.
• W4315619061 hasConceptScore W4315619061C196166836 @default.
• W4315619061 hasConceptScore W4315619061C203014093 @default.
• W4315619061 hasConceptScore W4315619061C2778559949 @default.
• W4315619061 hasConceptScore W4315619061C2779338263 @default.
• W4315619061 hasConceptScore W4315619061C2780007613 @default.
• W4315619061 hasConceptScore W4315619061C2781087989 @default.
• W4315619061 hasConceptScore W4315619061C2781184567 @default.
• W4315619061 hasConceptScore W4315619061C553184892 @default.
• W4315619061 hasConceptScore W4315619061C71924100 @default.
• W4315619061 hasConceptScore W4315619061C8891405 @default.
• W4315619061 hasFunder F4320326620 @default.
• W4315619061 hasFunder F4320337356 @default.
• W4315619061 hasIssue "1" @default.
• W4315619061 hasLocation W43156190611 @default.
• W4315619061 hasLocation W43156190612 @default.
• W4315619061 hasLocation W43156190613 @default.
• W4315619061 hasOpenAccess W4315619061 @default.
• W4315619061 hasPrimaryLocation W43156190611 @default.
• W4315619061 hasRelatedWork W2018626937 @default.
• W4315619061 hasRelatedWork W2092980349 @default.
• W4315619061 hasRelatedWork W2112285079 @default.
• W4315619061 hasRelatedWork W2180805647 @default.
• W4315619061 hasRelatedWork W2381114606 @default.
• W4315619061 hasRelatedWork W2409308676 @default.
• W4315619061 hasRelatedWork W2890187591 @default.
• W4315619061 hasRelatedWork W3029343576 @default.
• W4315619061 hasRelatedWork W3032821516 @default.

• next